Related Experiment Video
Updated: Apr 24, 2026
Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
Published on: February 24, 2023
CAR T cells for pediatric CNS tumors: Clinical experience and reverse translational opportunities
Kun-Wei Song1,2, Aanchal Preet Kaur2,3, Sneha Ramakrishna2,3
1Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Abstract:
Central nervous system (CNS) tumors are one of the leading causes of cancer-related mortality in children and young adults. Despite decades of research, effective treatments for these tumors are still lacking and new therapeutic options are urgently needed. While chimeric antigen receptor (CAR) T cell therapies have revolutionized the treatment of hematologic malignancies, these cellular therapies are only beginning to show evidence of activity in CNS tumors. In this review, we will discuss current CAR T cell clinical trials with a focus on trials in the pediatric CNS tumor space. In addition, we will explore the power of reverse translation-defined by applying clinical research insights from bedside-to-bench to understand the mechanisms of CAR T cell success or failure in patients-for CNS tumor CAR T cells. Employing the full cycle of translational research, novel CAR T cell therapies are being tested in the clinic and reverse translational studies are being assessed at the bench. Combining these data, the CNS CAR T cell field is poised to iteratively improve CAR T cells for children and young adults with CNS tumors.
Insights
Chimeric antigen receptor (CAR) T cell therapy shows promise for pediatric central nervous system (CNS) tumors. Research combines clinical trials and bench studies to improve these novel cancer treatments for young patients.
Area of Science:
- Oncology
- Immunotherapy
- Pediatric Medicine
Background:
- Central nervous system (CNS) tumors are a major cause of mortality in children and young adults.
- Existing treatments for CNS tumors are limited, necessitating novel therapeutic strategies.
- Chimeric antigen receptor (CAR) T cell therapy has transformed hematologic cancer treatment but is nascent in CNS tumors.
Purpose of the Study:
- To review current CAR T cell clinical trials, particularly in pediatric CNS tumors.
- To explore reverse translation's role in understanding CAR T cell efficacy in CNS tumors.
- To highlight the synergy between clinical and bench research for advancing CNS CAR T cell therapy.
Main Methods:
- Review of ongoing CAR T cell clinical trials in pediatric CNS tumors.
- Analysis of reverse translational research applying clinical findings to basic science.
- Integration of data from clinical studies and laboratory investigations.
Main Results:
- CAR T cell therapy is emerging as a potential treatment for pediatric CNS tumors.
- Reverse translation provides critical insights into CAR T cell mechanisms of action and resistance.
- Iterative improvements in CAR T cell therapy are driven by combined translational research.
Conclusions:
- The field of CAR T cell therapy for CNS tumors is advancing rapidly.
- Combining clinical trial data with reverse translational research is key to optimizing CAR T cells.
- This integrated approach holds significant promise for improving outcomes for young patients with CNS tumors.
More Related Videos
12:55Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022